Disc Medicine, Inc. (IRON) Stock
Healthcare · Biotechnology · Member of Other US Stocks
Disc Medicine, Inc. (IRON) closed at USD 55.74 on 2026-10-14, a change of -36.4 % over the past year, with a market capitalization of USD 2.17B.
Disc Medicine, Inc. recent closing prices
| Date | Close (USD) |
|---|---|
| 2026-10-14 | 55.74 |
| 2026-10-13 | 56.60 |
| 2026-10-12 | 60.48 |
| 2026-10-09 | 62.06 |
| 2026-10-08 | 60.77 |
| 2026-10-07 | 61.18 |
| 2026-10-06 | 61.65 |
The most recent trading day is not shown. For full charts and indicators use the analysis page.
Disc Medicine, Inc. key figures
- Previous close
- USD 55.74 (2026-10-14)
- 1-year change
- -36.4 %
- Market cap
- USD 2.17B
- Enterprise value
- USD 1.52B
- P/E ratio (trailing)
- -8.74
- P/E ratio (forward)
- -8.00
- EPS (trailing)
- -6.48
- EPS (forward)
- -7.08
- PEG ratio
- n/a
- Price to book
- 3.37
- Revenue growth
- n/a
- Earnings growth
- n/a
- Dividend per share (trailing)
- 0.00
- Short ratio
- 12.69
- Employees
- 165
- Analyst consensus (third-party)
- strong_buy
Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.
About Disc Medicine, Inc.
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. It also develops preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. The company was founded in 2017 and is headquartered in Watertown, Massachusetts.
Technical indicators and comparison
Show RSI, MACD, EMA, CCI and ADX for Disc Medicine, Inc. and compare it with other stocks.
Analyze IRONAll Other US Stocks stocksStock-scoring.com provides this page for information only. It is not investment advice or a recommendation to buy or sell Disc Medicine, Inc. shares.